Recommendation of the President – Tyrvaya (varenicline)

On 20 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 27/2026 on the legitimacy of issuing approvals for the reimbursement of the medicinal product Tyrvaya (varenicline) for the indication: treatment-resistant severe dry eye syndrome

Publication in Public Information Bulletin (BIP) >>